ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 11, 2022 (GLOBE NEWSWIRE) — Molecular Partners AG (MOLNMOLN, a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that members of its management team will participate in two upcoming investor events. In addition, the Company will publish its Q1 2022 earnings report on May 12, after the close of trading at the NASDAQ exchange.
- 2022 RBC Capital Markets Global Healthcare Conference, in-person, May 17-18, 2022
- Fireside chat – Tuesday, May 17, 2022, at 9:00am ET
- BioEquity Europe 2022 – virtual 1×1 meetings, Monday-Tuesday, May 23-24, 2022
- Virtual presentation made available on-demand
Presentations will be made available through the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter – @MolecularPrtnrs
For further details, please contact: Seth Lewis email@example.com Tel: +1 781 420 2361 Shai Biran, Ph.D. firstname.lastname@example.org Tel: +1 978 254 6286 Thomas Schneckenburger, European IR & Media email@example.com Tel: +41 79 407 9952